The Global Health Body Issues Alert Over Critical Shortage of Weight-Loss Medications

Fewer than a tenth of people that would benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it releases its initial recommendations on the therapies.

Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging broader and more equitable access to this class of drugs.

Per estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.

"The latest guidelines recognises that excess weight is a chronic disease that can be treated with thorough and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and distribution challenges are significant obstacles to widespread access to the jabs that can aid individuals in losing considerable weight, says the organization.

Weight-Loss Drug Shortage

Despite the present most optimistic outlook, the supply of such drugs would only suffice for approximately 100 million people – less than 10% of eligible patients, as stated by the health organization.

The guideline encourages nations and manufacturers to increase availability, through strategies like licensing agreements.

A patent on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.

How Weight-Loss Injections Function

These medications replicate a natural hormone to slow digestion, suppress the appetite and enhance satiety so people eat less.

People typically start to lose weight within a few weeks of beginning the regular doses.

Studies indicates people may regain a significant portion after a year of halting the drug, as their typical appetite come back.

Being overweight or obese increases your risk for experiencing medical conditions, including diabetes, heart disease, stroke, and certain cancers.

Obesity impacts individuals in all nations and was responsible for millions of fatalities worldwide in 2024, according to the health agency.